OFEV Efficacy Supported in a New Study

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

PF_ofev efficacy

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015).

The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety of nintedanib (administered at 150 mg, twice a day) in patients with IPF when compared to patients treated with a placebo.

 

Read more about it:  https://bit.ly/1MhGtCQ

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

efficacy, OFEV® (nintedanib), pulmonary fibrosis

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums

Recent Posts


Recommended reading